Heart Metabolics Limited
Records under this name other than patents Heart Metabolics Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Heart Metabolics Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,470,806 | Perhexiline for treating chronic heart failure Lapsed on the fee record Ended Jun 25, 2021 · USPTO record | Lapsed on the fee record | Ended Jun 25, 2021 | USPTO record |
| US 8,440,697 | Treatment of heart failure Lapsed on the fee record Ended May 14, 2021 · USPTO record | Lapsed on the fee record | Ended May 14, 2021 | USPTO record |
| US 9,468,634 | Treatment of heart failure Lapsed on the fee record Ended Oct 18, 2020 · USPTO record | Lapsed on the fee record | Ended Oct 18, 2020 | USPTO record |
| US 9,457,017 | Treatment of heart failure Lapsed on the fee record Ended Oct 4, 2020 · USPTO record | Lapsed on the fee record | Ended Oct 4, 2020 | USPTO record |
| US 8,697,677 | Perhexiline for treating chronic heart failure Lapsed on the fee record Ended Apr 15, 2018 · USPTO record | Lapsed on the fee record | Ended Apr 15, 2018 | USPTO record |
| US 8,697,728 | Perhexiline for use in the treatment of hypertrophic cardiomyopathy (HCM) Lapsed on the fee record Ended Apr 15, 2018 · USPTO record | Lapsed on the fee record | Ended Apr 15, 2018 | USPTO record |